These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19881512)

  • 21. Management of autoimmune hepatitis.
    Mayo MJ
    Curr Opin Gastroenterol; 2011 May; 27(3):224-30. PubMed ID: 21451411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving new therapies of autoimmune hepatitis.
    Vierling JM; Flores PA
    Clin Liver Dis; 2002 Aug; 6(3):825-50, ix. PubMed ID: 12362583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
    Wolf DC; Bojito L; Facciuto M; Lebovics E
    Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Case report: a series of autoimmune diseases].
    Duclos-Vallée JC
    Gastroenterol Clin Biol; 2007 Mar; 31(3):354-6. PubMed ID: 17396101
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases].
    Harboe E; Gøransson L; Wildhagen K; Omdal R
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1650-2. PubMed ID: 15976831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.
    Richardson PD; James PD; Ryder SD
    J Hepatol; 2000 Sep; 33(3):371-5. PubMed ID: 11019991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
    Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical management of autoimmune hepatitis.
    Pape S; Schramm C; Gevers TJ
    United European Gastroenterol J; 2019 Nov; 7(9):1156-1163. PubMed ID: 31700628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and prospective pharmacotherapy for autoimmune hepatitis.
    Czaja AJ
    Expert Opin Pharmacother; 2014 Aug; 15(12):1715-36. PubMed ID: 24961409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus as second-line therapy in acute severe autoimmune hepatitis.
    Efe C
    Scand J Gastroenterol; 2021 Mar; 56(3):298. PubMed ID: 33369499
    [No Abstract]   [Full Text] [Related]  

  • 31. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
    Czaja AJ; Carpenter HA
    J Clin Gastroenterol; 2005 Oct; 39(9):819-25. PubMed ID: 16145346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Think STOP before going "off-label".
    Miniuk GY
    Can J Gastroenterol; 2004 May; 18(5):287-8. PubMed ID: 15202434
    [No Abstract]   [Full Text] [Related]  

  • 34. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
    Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
    Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use.
    Ytting H; Larsen FS
    Scand J Gastroenterol; 2015 Aug; 50(8):1025-31. PubMed ID: 25862144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.
    Aw MM; Dhawan A; Samyn M; Bargiota A; Mieli-Vergani G
    J Hepatol; 2009 Jul; 51(1):156-60. PubMed ID: 19446911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoimmune hepatitis: current knowledge.
    Vajro P; Paolella G
    Clin Res Hepatol Gastroenterol; 2012 Jun; 36(3):284-6. PubMed ID: 22521122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Yu ZJ; Zhang LL; Huang TT; Zhu JS; He ZB
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):873-877. PubMed ID: 31150366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    De Lemos-Bonotto M; Valle-Tovo C; Costabeber AM; Mattos AA; Azeredo-da-Silva ALF
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):212-216. PubMed ID: 29227329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.